Skip to main content
. 2020 Feb 1;318(2):H326–H328. doi: 10.1152/ajpheart.00004.2020

Fig. 1.

Fig. 1.

A: schematic representation of canonical activin, growth differentiation factor 11 (GDF11), and myostatin (MSTN) signaling through the activin type II receptor/transforming growth factor-β (TGF-β) receptor I (ACTRII/TGFBRI) or ACTRII/activin receptor type-1β (ACTRII/ACTR1B) receptor. B: strategy implemented by Castillero et al. (3) to inhibit activin type II receptor signaling. Animals were administred either Myo-Fc (a, dashed square) or follistatin along with TGFBRI inhibitor (TGFi; b, dashed square).